Novo Nordisk (NVO) reported Wednesday Q4 earnings of 6.34 Danish kroner ($0.88) per diluted share, up from 4.91 kroner a year earlier.
Analysts polled by FactSet expected 5.96 kroner.
Sales for the quarter ended Dec. 31 were 85.68 billion kroner, up from 65.86 billion kroner a year earlier.
Analysts polled by FactSet expected 80.7 billion kroner.
For 2025, the company expects sales growth at constant exchange rates of 16% to 24%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.